- The report contains detailed information about Pharmaniaga Bhd that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Pharmaniaga Bhd. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Pharmaniaga Bhd financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Pharmaniaga Bhd competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Pharmaniaga Bhd business.
About Pharmaniaga Bhd
Pharmaniaga Berhad operates as an investment holding company that manufactures generic pharmaceuticals in Malaysia. The principal activities of the group consist of research and development, manufacturing, marketing, distribution and trading of pharmaceutical products; purchasing, storage and distribution of pharmaceutical and medical products to government hospitals and private institutions; provision of information technology solutions and systems support services; provision of diagnostic laboratory testing services; and medical planning and hospital equipping activities.
In 2004, the company launched products, such as Innoherb, a health supplement range from France; Ticlopidine, which reduces the probability of future stroke events in stroke patients; Clarithromycin Suspension, an antibiotic for treatment of bacterial infections in children; Itraconazole, for the treatment of fungal infections and Paracetamol C&F (Cold and Flu), which is a remedy for colds and flu. A total of 20 products, were registered in 2004.
The acquisition of 55 per cent interest in PT Millennium Pharmacon International Tbk (MPI) in Indonesia was completed in December 2004. MPI is the distributor of pharmaceutical and healthcare related products for local and foreign principals in Indonesia. Some of MPIs major principals include Merck, Meiji Indonesia and Lapi Laboratories. MPI had a nationwide distribution network of 24 branches as of December 31, 2004. The main warehouses are located in three cities; namely Jakarta, Bandung and Surabaya, all are located in Java Island.
Medical Products and Services involves in the business of providing hospital equipping services, as well as procuring and distributing medical and related hospital equipment.
On the local front, the company kicked off the pilot project for the Integrated Hospital Inventory System, extending the existing computerized system to cover areas, such as the main store, ward supply pharmacy, satellite store and ward unit within government hospitals.
The company signed up a contract with a major private hospital group in Thailand for the development and implementation of the Internet based Demand Chain Management (DCM) system. The system to be implemented in Thailand would model after its Pharma Net set up in Malaysia.
The company offers Computer Disaster Recovery Plan (CDRP) for UEM World Berhad (UEM World) which addresses the recovery of UEM Worlds mission critical processing operations in the event of a disaster. Kualiti Alam Sdn Bhd, a subsidiary company of UEM World, has appointed the company as their consultant in developing their CDRP integrated Waste Management Centre in Bukit Pelanduk, Negeri Sembilan. Other parties have also expressed interest in Pharmaniaga Solutions capabilities in the area of Business Continuity Planning, in particular. The companys subsidiaries are Pharmaniaga Manufacturing and Pharmaniaga Logistics.
The company has strategic alliances with local research institutions, such as the Malaysian Institute for Nuclear Technology; MARDI; and the National Institute for Natural Products, Vaccines and Biologicals in the field of biotechnology.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. PHARMANIAGA BHD COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. PHARMANIAGA BHD BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. PHARMANIAGA BHD SWOT ANALYSIS
4. PHARMANIAGA BHD FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. PHARMANIAGA BHD COMPETITORS AND INDUSTRY ANALYSIS
5.1. Pharmaniaga Bhd Direct Competitors
5.2. Comparison of Pharmaniaga Bhd and Direct Competitors Financial Ratios
5.3. Comparison of Pharmaniaga Bhd and Direct Competitors Stock Charts
5.4. Pharmaniaga Bhd Industry Analysis
5.4.1. Healthcare Services Industry Snapshot
5.4.2. Pharmaniaga Bhd Industry Position Analysis
6. PHARMANIAGA BHD NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. PHARMANIAGA BHD EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. PHARMANIAGA BHD ENHANCED SWOT ANALYSIS2
9. MALAYSIA PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. PHARMANIAGA BHD IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. PHARMANIAGA BHD PORTER FIVE FORCES ANALYSIS2
12. PHARMANIAGA BHD VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Pharmaniaga Bhd Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Pharmaniaga Bhd Key Executives
Key Executives Biographies1
Key Executives Compensations1
Pharmaniaga Bhd Major Shareholders
Pharmaniaga Bhd History
Pharmaniaga Bhd Products
Revenues by Segment
Revenues by Region
Pharmaniaga Bhd Offices and Representations
Pharmaniaga Bhd SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Pharmaniaga Bhd Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Pharmaniaga Bhd Capital Market Snapshot
Pharmaniaga Bhd Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Healthcare Services Industry Statistics
Pharmaniaga Bhd Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Pharmaniaga Bhd Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Pharmaniaga Bhd Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Pharmaniaga Bhd 1-year Stock Charts
Pharmaniaga Bhd 5-year Stock Charts
Pharmaniaga Bhd vs. Main Indexes 1-year Stock Chart
Pharmaniaga Bhd vs. Direct Competitors 1-year Stock Charts
Pharmaniaga Bhd Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?